- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05526664
Omics Gaucher Study: Multiomic Approach (OmicsGaucher)
Omics Gaucher Study: Multiomic Approach To Describe The Gaucher Disease Treatment Dynamics In Comparison To Untreated Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Gaucher disease is one of the most common lysosomal storage disorders (LSD) and is an autosomal recessive inherited disorder, primed by mutation in the GBA1 gene which leads to a deficiency in β-glucocerebrosidase (GCase) activity and accumulation of its substrate glucosylceramide (GluCer)/-sphingosine (GluSph). The macrophages are the main cell type exhibiting a Gaucher disease phenotype. The large accumulation of GluCer and to a lesser extent that of GluSph lead to dysfunction in organs such as spleen, liver, bone marrow, and lungs.
However, a validated, reproducible, and broadly applicable tool to classify Gaucher Disease at any stage of the disease is still missing.
The development of new technologies, such as genomic analysis by next generation sequencing (NGS) and other "omics technologies," has advanced the molecular understanding and diagnosis of Rare Diseases
The current study will analyze the transcriptional and metabolomic profiles in blood, plasma and isolated monocytes from Gaucher patients and healthy controls with the aim to compare these profiles and to define how much a patient profile differs from a healthy one.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Filipa Curado, PhD
- Phone Number: +49 381 80113 841
- Email: clinical.studies@centogene.com
Study Locations
-
-
-
Hamburg, Germany
- UKE
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Gaucher Type 1 participants:
- Informed consent
- The participant is older than 18 years old
- The participant was diagnosed with Gaucher Type 1 disease
Gaucher Type 3 participants:
- Informed consent
- The participant is older than 18 years old
- The participant was diagnosed with Gaucher type 3 disease
Healthy participants:
- Informed consent
- The participant is older than 18 years old
- Healthy participants
Exclusion Criteria:
Gaucher Type I participants:
- The participant had any other clinically significant disease
- The participant had a recent (within 14 days) acute infection and/or vaccination
Gaucher Type 3 participants:
- Diagnosis of a significant CNS disease or cardiovascular disease other than Gaucher type 3
- The participant had a recent (within 14 days) acute infection and/or vaccination
Healthy participants:
- The participant had a recent (within 14 days) acute infection and/or vaccination
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Gaucher Type 1
|
Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics
|
Gaucher Type 3
|
Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics
|
Healthy Volunteer
|
Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OMICS DATA
Time Frame: 12 months
|
investigate the transcriptomic and metabolomic changes in blood, plasma and isolated monocytes from Gaucher patients and healthy controls.
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Peter Bauer, MD, CENTOGENE GmbH
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Lipid Metabolism Disorders
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Sphingolipidoses
- Lysosomal Storage Diseases, Nervous System
- Lipidoses
- Lipid Metabolism, Inborn Errors
- Gaucher Disease
Other Study ID Numbers
- OG 01-2022
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gaucher Disease
-
KemPharm Denmark A/STerminatedGaucher Disease, Type 1 | Gaucher Disease, Type 3India
-
AVROBIOWithdrawn
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited Kingdom, United States
-
Genzyme, a Sanofi CompanyActive, not recruitingGaucher Disease Type 1 | Gaucher Disease Type 3Germany, United States, Japan, United Kingdom
-
Baylor Research InstituteTexas Scottish Rite Hospital for ChildrenWithdrawnGaucher Disease Type 1 | Gaucher Disease Type 3United States
-
CANbridge (Suzhou) Bio-pharma Co., Ltd.RecruitingGaucher Disease, Type 1 | Gaucher Disease, Type 3China
-
Cambridge University Hospitals NHS Foundation TrustMedical Research Council; National Institute for Health Research, United KingdomRecruitingGaucher Disease, Type III | Gaucher Disease, Type IUnited Kingdom
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited States
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited Kingdom, Israel, South Africa, United States
-
Freeline TherapeuticsRecruitingGaucher Disease, Type 1Spain, Israel, United States, United Kingdom, Brazil, Germany, Paraguay
Clinical Trials on Genetic testing and Omics analysis
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLynch Syndrome | Relatives | Endometrial Carcinoma | Endometrial AdenocarcinomaUnited States
-
Thomas Jefferson UniversityProstate Cancer FoundationActive, not recruitingBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8United States
-
Augusta UniversityRecruitingOvarian Cancer | Endometrial Cancer | Peritoneal CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)Active, not recruitingMetastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8United States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMalignant Solid Neoplasm | Breast Carcinoma | Digestive System Neoplasm | Skin Carcinoma | Malignant Female Reproductive System Neoplasm | Metastatic Malignant Neoplasm of Unknown Primary | Malignant Head and Neck Neoplasm | Malignant Brain Neoplasm | Malignant Central Nervous System Neoplasm | Malignant... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)TerminatedMetastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Colon Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityRecruitingMalignant Solid Neoplasm | Lynch Syndrome | Hematopoietic and Lymphoid System Neoplasm | Breast Ductal Carcinoma In Situ | Hereditary Neoplastic Syndrome | BRCA1/2-Associated Hereditary Breast and Ovarian Cancer SyndromeUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingGlioma | Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Melanoma | SarcomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Breast Carcinoma | Digestive System Carcinoma | Head and Neck Carcinoma | Skin Carcinoma | Malignant Female Reproductive System Neoplasm | Malignant Brain Neoplasm | Carcinoma of Unknown Primary | Central Nervous System Carcinoma | Genitourinary System Carcinoma | Malignant Musculoskeletal...United States